Literature DB >> 26925960

Haematological cancers: Lenalidomide--SPRINT to a new standard?

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26925960     DOI： 10.1038/nrclinonc.2016.34

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Authors:  Marek Trněný; Thierry Lamy; Jan Walewski; David Belada; Jiri Mayer; John Radford; Wojciech Jurczak; Franck Morschhauser; Julia Alexeeva; Simon Rule; Boris Afanasyev; Kamil Kaplanov; Antoine Thyss; Alexej Kuzmin; Sergey Voloshin; Kazimierz Kuliczkowski; Agnieszka Giza; Noel Milpied; Caterina Stelitano; Reinhard Marks; Lorenz Trümper; Tsvetan Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Luca Arcaini
Journal:  Lancet Oncol       Date:  2016-02-16       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.